Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 4, 2009, Pages 433-439

  De Vijlder, H C ^a   Middelburg, T ^a   De Bruijn, H S ^a   Martino Neumann, H A ^a   Sterenborg, H C J M ^a   Robinson, D J ^a   De Haas, E R M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aminolevulinic acid; Photochemotherapy; Skin neoplasms

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; PHOTOFRIN;

ANALGESIA; BASAL CELL CARCINOMA; BOWEN DISEASE; ESTHETICS; HISTORY OF MEDICINE; HUMAN; PHOTODYNAMIC THERAPY; REVIEW; SKIN CANCER; TREATMENT OUTCOME;

EID: 72249108188     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochenschr 1903;47:2042-2044
2. Von Tappeiner H, Jodlbauer A. Ueber Wirkung de Photodynamischen (fluorieszierende) Stoffe auf Protozoan und Enzyme. Dtch Arch Klin Med 1904;80:427-487
3. Hausmann W. Die sensibilisierede Wirkung des Hematoporphrins. Biochem Z 1911;30:276-316.
4. Schwartz SK, Absolon K, Vermund H. Some relationships of porphrins, X-rays and tumours. Univ Minn Med Bull 1955;27:7-8.
5. Meyer-Betz. Untersuchungen uber die Biologische (photodynamische) Wirkung des Hamatoporphyrins und anderer Derivative des Blut- und Galenfarbstoffs. Dtsch Arch Klin Med 1913;112:476-503.
6. Spikes JD. Chlorins as photosensitizers in biology and medicine. J Photochem B Biol 1990;6:259-274
7. Chan WS, Svensen R, Philips D, Hart IR. Cell uptake, distribution and response to aluminium chloro-sulphonated phthalocyamine, a potential anti-tumour photosensitizer. Br J Cancer 1986;53:255-263 (Pubitemid 16095566)
8. Kennedy JC, Pottier JH, Ross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience .J Photochem Photobiol B Biol 1990;6:143-148
9. Fink-Puches R, Hofer A, Smolle J, Kerl H, Wolf P. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B Biol 1996;34: 95-96
10. Omrod D, Jarvis B. Topical aminolevulinic acid HCL photodynamic therapy. Am J Clin Dermatol 2000;1:133-139
11. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolevulinc acid for superficial primary and secondary skin cancer. Br J Dermatol 1994;69:605-608 (Pubitemid 24076490)
12. Stables GIM, Stringer R, Robinson DJ, Ash DV. Large patches of Bowen's disease treated by topical aminolevulinic acid photodynamic therapy. Br J Dermatol 1997;136:957-960
13. Solar AM, Warloe T, Berner A, Giercksky KE. A follow up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl-aminolevulinate photodynamic therapy alone and with prior curettage. Br J Dermatol 2001;145:467-471
14. Basset-Sequin N, Ibbotson S, Emtestam L. Photodynamic therapy using Metvix is as efficacious as cryotherapy in BCC, with better cosmetic results. J Eur Acad Dermatol Venereol 2001;15:226.
15. Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE et al. Topical methyl aminolevulinate photodynamic therapy in patients with basall cell carcinoma prone to complications and poor cosmetic outcome with conventional therapy. Br J Dermatol 2003;149:1242-1249 (Pubitemid 38058101)
16. Foley P, Freeman M, Siller G, Gebauer K, Murrell D, Barnetson R et al. A phase III randomized study comparing photodynamic therapy (PDT) using Metvix or placebo cream in nodular basal cell carcinoma (BCC). Australas J Dermatol 2003;44:A5.
17. Vinciullo C, Elliott T, Francis D, Gebauer K, Spelman L, Nguyen R et al. Photodynamic therapy with methyl aminolevulinate for "difficult to treat" basal cell carcinoma. Br J Dermatol 2005;152:765-772
18. Rhodes LE, De Rie M, Enstro Y, Groves R, Morken T, Goulden V et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicentre randomised prospective trial. Arch Dermatol 2004;140:17-23.
19. Wulf HC, Phillipsen P. Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy. Br J Dermatol 2004;150:143-145
20. Havlet AK, Ward TH, Moore JV. DNA damage and repair in Gorlin syndrome and normal fibroblasts after aminolevulinic acid phototherapy: a comet assay study. Photochem Photobiol 2003;78:337-341
21. Finlan LE, Kernohan NM, Thomson G, Beattie PE, Hupp TR, Ibbotson SH. Differential effects of 5-aminolevulinic acid photodynamic therapy and psoralen and ultraviolet therapy on p53 phosphorylation in normal human skin in vivo. Br J Dermatol 2005;153:1001-1010 (Pubitemid 41540769)
22. Gibson SL, Havens JJ, Foster TH, Hilf R. Time-dependent intracellular accumulation of ‰-aminolevulinic acid, induction of porphyrin synthesis and subsequent phototoxicity. Photochem Photobiol 1997;65:416-421 (Pubitemid 27158973)
23. Rud E, Gederaas O, Hogset A, Berg K. 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000;71:640-647
24. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A et al. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 2005;218:133-147 (Pubitemid 40655323)
25. Uehlinger P, Zellweger M, Wagnières G, Juillerat-Jeanneret L, van den Bergh H, Lange N. 5-aminolevulinic acid and its derivatives: physical chemical properties and protoporphrin IX formation in cultured cells. J Photochem Photobiol B 2000;54:72-80.
26. Gaullier JM, Gèze M, Santus R, Sa e Melo T, Mazière JC, Bazin M et al. Subcellualr localisation of and photosensitization by protoporphyrin IX in human keratinocytes and fibroblasts cultivated with 5-aminolevulinic acid. Photochem Photobiol 1995;62:114-122
27. Gederaas OA, Holroyd A, Brown SB, Vernon D, Moan J, Berg K. 5-Aminolevulinic acid methyl ester transport on amino acid carriers in a human colon adenocarcinoma cell line. Photochem Photobiol 2001;73:721-732
28. Datta SN, Loh CS, MacRobert AJ, Whatley SD, Matthews PN. Quantitative studies of the kinetics of 5-aminolaevulinic acid induced fluorescence in bladder transitional cell carcinoma. Br J Cancer 1998;78:1113-1118
29. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of 5-aminolevulinic acid methylester. Photochem Photobiol 2000;71:640-647
30. Moan j, Ma LW, Juzeniene A, Iani V, Juzenas P, Apricena F et al. Pharmacology of protoporphyrine IX in nude mice after application of ALA and ALA esters. Int J Cancer 2003;103:132-135
31. Van den Akker JTHM, Iani V, Star WM, Sterenborg HJCM, Moan J. Topical application of 5-aminolevulinic acid hexyl aster and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum comeum. Photochem Photobiol 2000;72:681-689
32. Van den Akker JTHM, Holroyd JA, Vernon DI, Sterenborg HJCM, Brown SB. Comparative in vitro percutaneous penetration of 5-aminolevulinic acid and two of its esters through excised hairless mouse skin. Las Surg Med 2003;3:173-181
33. Van den Akker JHTM, de Bruijn HS, Beijersbergen Henegouwen GJM, Star WM, Sterenborg HJCM. Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB induced early skin cancer. Photochem Photobiol 2000;72:399-406.
34. Warloe T, Heyerdahl H, Peng Q, Giercksky KE. Photodynamic therapy with 5-aminolevulinc acid induced porphyrins and skin pentration enhancer for basal cell carcinoma. SPIE 1994;2371:226-235
35. Curnow A, McIloy BW, Postle-Hacon MJ, Porter JB, Mac Robert AJ, Brown SG. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridione iron chelating agents. Br J Cancer 1998;78:1278-1282 (Pubitemid 28495237)
36. Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol 2008;159:387-393
37. Peng Q, Warloe T, Moan J Heyerdahl H, Steen HB, Nesland JM et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906-913
38. Rhodes LE, Tsoukas MM, Anderson RR, Kollia N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J Invest Dermatol 1997;108:87-91.
39. van der Veen N, de Bruijn HS, Star WM. Kinetics of PpIX fluorescence after topical ALA application to normal and tape stripped human skin [Thesis]. [Rotterdam]: University of Rotterdam; 1999. p. 101-118
40. Gerritsen MJP, Smits T, Kleinpenning MM, van de Kerkhof PC, van Erp PE. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009;218:192-202.
41. Tope WD, Ross EV, Kollias N, Martin A, Gillies R, Rox Anderson R. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral aminolevulinc acid. Photchem Photobiol 1998;67:249-255 (Pubitemid 128472266)
42. Fan KFM, Hopper C, Speight PM, Buonaccorsi G, Mac Robert AJ, Brown SG. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer (Phila) 1996;78:1374-1383
43. Barr H, Stepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-585
44. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photchem Photobiol 1998;67:140-149
45. Hua Z, Gibson SL, Foster TH, Hilf R. Effectiveness of aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo. Cancer Res 1995;55:1723-1731
46. Pogue BW, Hasan T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat Res 1997;147:551-559 (Pubitemid 27204091)
47. Morton CA, Whitehurts C, Moseley H, McColl JH, Moore JV, MacKie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-771
48. Haller JC, Cairnduff F, Slack G, Schofield J, Whitehurst C, Tunstall R et al. Routine double treatments of superficial basal cell carcinomas using aminolevulinic acid-based photodynamic therapy. Br J Dermatol 2000;143:1270-1275
49. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17-23.
50. Messmann H, Milkvy P, Buonaccorsi G, Davies CL, Mac Robert AJ, Brown SG. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer 1995;72:589-594
51. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Protoporphyrin IX fluorescence photobleaching during ALA mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. Photochem Photobiol 1999;69:61-70.
52. Curnow A, McIlroy BW, Postle-Hacon MJ, Mac Robert AJ, Brown SG. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 1999;69:71-76 (Pubitemid 129555463)
53. van der Veen N, Leengoed HLL, Star WM. In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acidinduced porphyrin: increased damage after multiple irradiations. Br J Cancer 1994;70:867-872
54. van der Veen N, Hebeda KM, de Bruijn HS, Star WM. Photodynamic effectiveness and vasoconstriction in hairless mouse skin after topical 5-aminolevulinic acid and single- or two-fold illumination. Photochem Photobiol 1999;70:921-929
55. de Bruijn HS, van der Veen N, Robinson DJ, Star WM. Improvement of systemic 5-aminolevulinic acid photodynamic therapy in-vivo using light fractionation with a 75-minute interval. Cancer Res 1999;59:901-904 (Pubitemid 29086746)
56. Robinson DJ, de Bruijn HS, de Wolf J, Sterenborg HJCM, Star WM. Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol 2000;72:794-802.
57. Robinson DJ, de Bruijn HS, Star WM, Sterenborg HJCM. Dose and timing of the first light fraction in two fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin Photochem Photobiol 2003;77:319-323
58. de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJCM, Robinson DJ. Fractionated illumination after topical application of 5- aminolevulinic acid on normal skin of hairless mice; the influence of the dark interval. J Photochem Photobiol B Biol 2006;85:184-90.
59. Star WM, van't Veen Robinson DJ, Munte K, de Haas ERM, Sterenborg HJCM. Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two hour interval: long-term follow-up. Acta Derm Venereol 2006;86:412-417
60. de Haas ERM, Kruijt B et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006;126:2679-2686
61. de Haas ERM, Sterenborg HJCM, Sterenborg HJ, Martino Neumann HA, Robinson DJ. Response of Bowen Disease to ALA-PDT using a single and a 2fold illumination scheme. Arch Dermatol 2007;1343:264-265
62. Leibovitch I, Huigol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol 2005;52:997-1002. (Pubitemid 40732538)
63. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-771
64. Morton CA. Topical photodynamic therapy for Bowen's disease. Austr J Derm 2005;46:S11.
65. Varma S, Wilson H, Kurwa HA, Gambles B, Charman C, Pearse AD et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001;144:567-574 (Pubitemid 32232013)
66. de Haas ERM, de Vijlder HC, Sterenborg HJ, Neumann HA, Robinson DJ. Fractionated ALA-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008;22:426-430
67. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage.Br J Dermatol 2001;145:467-471
68. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V et al. Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17-23.
69. Kuijpers DI, Thissen MR, Thissen CA, Neumann HAM. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006;5:642-645
70. Robinson DJ, de Bruijn HS, Star WM, Sterenborg HJ. Dose and timing of the first light fraction in two-fold illumination schemes for topical ALA-mediated photodynamic therapy of hairless mouse skin. Photochem Photobiol 2003;77:319-323
71. Presser SE, Taylor JR. Clinical diagnostic accuracy of basal cell carcinoma. J Am Acad Dermatol 1987;16:988-990
72. Oseroff AR. ODT for cutaneous malignancies: clinical applications and basic mechanisms. Photochem Photobiol 1998;67:17-8S.
73. Martin A, Tpoe WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995;287:665-674
74. Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R et al. Optimization of photodynamic therapy with a novel self-adhesive 5 aminolevulinc acid patch: result of two randomized controlled phase II studies. Brit J Dermatol 2009;160:1066-1074
75. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007;56:125-143 (Pubitemid 44969292)
76. Mosterd K, Thissen MRTM, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG et al. Fractionated 5-aminolevulinic acid photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinomas: results of a randomized controlled trial. Brit J Dermatol 2008;159:864-870